About 88 percent of votes cast were in favor of the deal — which will catapult the Japanese company into a new league of drug industry giants. Takeda will join the ranks of the world’s top 10 drugmakers and gain a large portfolio of rare disease treatments.
With the deal, the drugmaker will also become one of the most indebted companies. Its high debt levels were the top concern of a group of shareholders, including descendants of the company’s founder, who lobbied to block the cash-and-stock merger.
Takeda CEO Christophe Weber made a promise to shareholders to turn the deal profitable by slashing costs, predicting an annual savings of $1.4 billion three years after the deal is finalized. In addition, Takeda plans to shed up to $10 billion worth of non-core assets to minimize the debt burden of the deal.
In March, when Takeda first announced its intent to purchase Shire, the deal was valued at $62 billion. Currency fluctuations and a fall in Takeda’s share price lowered that valuation.
Shire stakeholders separately voted in favor of the deal.
More articles on pharmacy:
Walmart, 3 pharma companies sued over impure drugs
Justice Department wants to drop Supreme Court whistle-blower case against Gilead
GAO finds flaws in FDA’s orphan drug program: 6 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
